Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk. (28th November 2018)

• Record Type: Journal Article
• Authors: Terry, Mary Beth; Daly, Mary B; Phillips, Kelly Anne; Ma, Xinran; Zeinomar, Nur; Leoce, Nicole; Dite, Gillian S; MacInnis, Robert J; Chung, Wendy K; Knight, Julia A; Southey, Melissa C; Milne, Roger L; Goldgar, David; Giles, Graham G; Weideman, Prue C; Glendon, Gord; Buchsbaum, Richard; Andrulis, Irene L; John, Esther M; Buys, Saundra S; Hopper, John L
• Is Part Of: Journal of the National Cancer Institute. Volume 111:Number 3(2019)
• Page Start: 331
• Page End: 334
• Publication Date: 2018-11-28
• Subjects: Cancer -- Periodicals; Cancer -- Research -- Periodicals; 616.994
• DOI: 10.1093/jnci/djy182
• Languages: English
• ISSNs: 0027-8874

Abstract

Abstract: There remains debate about whether risk-reducing salpingo-oophorectomy (RRSO), which reduces ovarian cancer risk, also reduces breast cancer risk. We examined the association between RRSO and breast cancer risk using a prospective cohort of 17 917 women unaffected with breast cancer at baseline (7.2% known carriers of BRCA1 or BRCA2 mutations). During a median follow-up of 10.7 years, 1046 women were diagnosed with incident breast cancer. Modeling RRSO as a time-varying exposure, there was no association with breast cancer risk overall (hazard ratio [HR] = 1.04, 95% confidence interval [CI] = 0.87 to 1.24) or by tertiles of predicted absolute risk based on family history (HR = 0.68, 95% CI = 0.32 to 1.47, HR = 0.94, 95% CI = 0.70 to 1.26, and HR = 1.10, 95% CI = 0.88 to 1.39, for lowest, middle, and highest tertile of risk, respectively) or for BRCA1 and BRCA2 mutation carriers when examined separately. There was also no association after accounting for hormone therapy use after RRSO. These findings suggest that RRSO should not be considered efficacious for reducing breast cancer risk.